Esophageal cancer is the sixth deadly cancer with poor prognosis. The incidence and the prevalence rates are almost equal, and survival time is short (
1). Squamous cell carcinoma (SCC) and adenocarcinoma could be assumed as predominant histology for patients who are suffering from esophageal carcinoma (
2). More than 90% of esophageal cancers diagnosed in the worldwide have SCC origin. Small cell carcinoma has been seen in almost 1% of patients (
3) and mukoepidermoid carcinoma in less than 1% (
4). At the moment, despite the use of multimodality therapy, the 5-year survival rate is not even 50%. The utilization of auxiliary chemo-radiotherapy earlier revealed cancers with ESCCs, the most favorable result obtained for patients with high potential for lymph node metastasis (
5-
7). Radiotherapy plays a special role in tumor growth control in patients that are suffering from esophageal cancer. The new treatment method is assumed to ameliorate resection rates, decrease lymphatic metastases and increase survival time (
6). Today chemo-radiotherapy is accepted as a standard method in management of locally advanced ESCCs without surgery. After the use of combination therapy survival rate improved significantly and recurrence decreased in patients with ESCCs (
8). Esophageal cancer shows high radiosensitivity and it is assumed that the diversity in the pattern of gene expression is the main reason of diversities in the response of tumor cells to radiation (
9).
Molecular analysis of esophageal cancer cells have revealed overexpression of some genes. Irrespective of the doubtful etiological factors and patient origin, genetic irregularity that frequently occur in SCC are: a) tumor suppressor genes Changes, distinctly p53, conducive to changed DNA repetition and correction, apoptosis and cell proliferation; b) the cell cycle’s control detriment and cut the G1/S cell cycle checkpoint; and c) changes in oncogene function conducting to deregulation of cell signaling cascades (
10,
11). The p53 gene as a tumor suppressor gene induces apoptosis by up-regulating bax gene and also results in cell cycle arrest by down-regulating bcl-2 (
12-
14). Mdm2 in humans is called Hdm2 and it is a negative regulator for tumor suppressor p53 (
2,
15). Hdm2 is overexpressed in various types of cancer, for example non-small cell lung cancer, melanoma esophageal cancer, breast cancer, leukemia, sarcoma and non-Hodgkin’s lymphoma (
15). It is shown that a significant correlation between Mdm2 gene expression and p53 gene mutations. P53 missense mutations result in decreasing Mdm2 protein expression. In cancers with wild type (wt), p53 activity of p53 can be restored by inhibition of Hdm2; furthermore, in association with anti-tumor agents with apoptosis and inhibitory growth (
1,
15). Extinguishing of Hdm2 mRNA have immediately elevated MCF-7 cell apoptosis and reduced the cell reproduction (
2).